Anniversary: 50 years of glucocorticoid treatment in rheumatoid arthritis
Philip Showalter Hench ( Fig. 1 ) was awarded the only pressure and had low blood glucose levels. The results of the first treatment of the first patients were dramatic Nobel Prize in rheumatology for his work on glucocorticoids. The first patient he treated had rheumatoid [1, 8, 9] . There is an original coloured file in which Hench and his colleagues documented the functional arthritis (RA) and he administered Compound E (cortisone) on 21 September 1948 with almost miraculous status of their first patients climbing stairs before and during treatment with Compound E. When the patients effect [1] . The impact of this event has been captured [2] by dividing the history of rheumatology into 'BC' were switched to cholesterol treatment, serving as placebo, their functional status became worse [1] . This and 'AC' (before cortisol and after cortisol ). The identification and use of glucocorticoid treatment can legitimcorresponded quite well with the theory that RA was a disease with adrenal insufficiency and did not cause ately be seen as a major breakthrough in modern medicine. Since its discovery, cortisone and its equivaconcern. The new cortisone treatment of RA was applauded with great enthusiasm. Hench and Kendall lents have been shown to be life saving in a variety of diseases and conditions, including anaphylaxis, asthma, (along with Reichstein from Switzerland) were honoured with the Nobel Prize only 2 yr later [8], in 1950. A few intracranial compression, systemic lupus erythematosus and vasculitis. However, even after half a century, the sceptical voices were raised. Russel Cecil's was one of them: '... hypoadrenalism is not the answer to the use and potential for misuse of glucocorticoids in RA remain the subject of vigorous debate [3] [4] [5] [6] .
rheumatoid arthritis problem … Hench and Kendall have only given us two more drugs to fumble with' [9] . The clues which set Hench to investigate the adrenal cortex were his own observations that pregnancy and As time passed, it became more obvious that cortisone, and the derivatives subsequently developed, cause many jaundice ameliorate RA [7] . He hypothesized that in both conditions the improvement was caused by elevated side-effects when administered for long periods [3, 4, 10] . Although local and intra-articular use of glucocorticoids corticosteroid levels, and this observation directed him to work with Kendall, Slocumb and Polley in trying to provide benefit for RA sufferers [11], systemic treatment was placed as 'third line' in the treatment pyramid, isolate compounds found in the adrenal cortex. It was supposed (and may yet, in a way, turn out to be the following unsuccessful treatment with specific antirheumatoid drugs [4] . In practice, however, glucocorticase [16 ] ) that RA patients might have latent hypoadrenia, suggested by the clinical impression that RA coids are widely used in RA [6 ] . This is so even though there are surprisingly few well-designed, controlled clinpatients were asthenic, weak, sometimes had low blood choice for those with elderly-onset RA. Evidence for the erosion-preventing effect of low-dose glucocorticoid treatment in early RA is accumulating [20] [21] [22] , and glucocorticoids are used for 'bridging' therapy in patients starting gold, methotrexate and other second-line drugs [3, 4] . New prednisolone derivatives are being investigated for beneficial effects with a better safety profile [23] . Other developments in glucocorticoid therapy will certainly follow, perhaps linking treatment more closely to the diurnal rhythm of the HPA axis [24, 25] .
As Weiss has pointed out: 'No agents currently available are as effective as corticosteroids in alleviating the symptoms of rheumatoid arthritis' [4] . Glucocorticoid administration in one form or another is destined in its second half-century to find a better defined place in the treatment of RA.
